Medical approaches to primary hyperparathyroidism

Endocrinology and Metabolism Clinics of North America

Volumn 29, Issue 3, 2000, Pages 523-539

  Strewler, Gordon J ^b  

^a Medical Service   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM CHANNEL STIMULATING AGENT; CLODRONIC ACID; CYCLOFENIL; ESTROGEN; GESTAGEN; MITHRAMYCIN; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; PAMIDRONIC ACID; PHOSPHATE;

BONE DENSITY; CALCIFICATION; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PARATHYROID CARCINOMA; PARATHYROIDECTOMY; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; REVIEW;

EID: 0033810350     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(05)70149-3     Document Type: Article

References (77)

1. Regulation of calcium-parathyroid hormone feedback in primary hyperparathyroidism: Effects of bisphosphonate treatment
2. Studies in parathyroid physiology, III: The effect of phosphate ingestion in clinical hyperparathyroidism
3. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure: Rapid communication
4. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs
5. Estrogen replacement decreases the set point of parathyroid hormone stimulation by calcium in normal postmenopausal women
6. Control of hypercalcaemia of parathyroid carcinoma by immunization
7. A detailed evaluation of oral phosphate therapy in selected patients with primary hyperparathyroidism
8. Direct comparison in vivo and in vitro of suppressibility of parathyroid function by calcium in primary hyperparathyroidism
9. 2+-sensing receptor from bovine parathyroid
10. Calcium-regulated parathyroid hormone release in primary hyperparathyroidism: Studies in vitro with dispersed parathyroid cells
11. Secretory control in normal and abnormal parathyroid tissue
12. The extracellular calcium-sensing receptor: Its role in health and disease
13. Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats
14. Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent
15. Estrogen protection against bone resorbing effects of parathyroid hormone infusion: Assessment by use of biochemical markers
16. Estrogen replacement may be an alternative to parathyroid surgery for the treatment of osteoporosis in elderly postmenopausal women presenting with primary hyperparathyroidism: A preliminary report
17. Protein tyrosine kinase-mediated pathways in G protein-coupled receptor signaling
18. Drug treatment of primary hyperparathyroidism: Use of clodronate disodium
19. Aminohydroxypropylidene diphosphonate treatment of hypercalcemic crisis due to primary hyperparathyroidism
20. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro
21. Acute primary hyperparathyroidism
22. Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca(2+) receptor in rats
23. The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism
24. NPS R-568: A type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium
25. Treatment with oestrogens of primary hyperparathyroidism in postmenopausal women
26. The effect of ethinyloestradiol on calcium and phosphorus metabolism of postmenopausal women with primary hyperparathyroidism
27. Maximal PTH secretory rate and set point for calcium in normal subjects and patients with primary hyperparathyroidism: In vivo studies
28. Inorganic phosphate treatment of hypercalcemia of diverse etiologies
29. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism: A randomized, controlled trial
30. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia
31. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism
32. Clodronate in the medical management of hyperparathyroidism
33. 2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568
34. Normalization of hypercalcaemia of primary hyperparathyroidism by treatment with methallenestril, a synthetic oestrogen with low oestrogenicity
35. Treatment of primary hyperparathyroidism with cyclofenil: A synthetic stilbestrol derivative with minimal feminizing effects
36. Treatment of postmenopausal hyperparathyroidism with norethindrone: Effects on biochemistry and forearm mineral density
37. Two hundred eighty-six cases of parathyroid carcinoma treated in the US between 1985-1995: A National Cancer Data Base Report
38. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism
39. Metabolic effects of diphosphonate in primary hyperparathyroidism
40. Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: A population-based study
41. Mixed-effects modeling of the pharmacodynamic response to the calcimimetic agent R-568
42. Bisphosphonate therapy
43. Estrogens and progestins in the management of primary hyperparathyroidism
44. Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism
45. Effects of mild asymptomatic primary hyperparathyroidism on bone mass in women with and without estrogen replacement therapy
46. Thrombin receptor activation elicits rapid protein tyrosine phosphorylation and stimulation of the raf-1/MAP kinase pathway preceding delayed mitogenesis in cultured rat aortic smooth muscle cells: Evidence for an obligate autocrine mechanism promoting cell proliferation induced by G protein-coupled receptor agonist
47. Calcimimetic compounds: A direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism
48. Calcimimetics with potent and selective activity on the parathyroid calcium receptor
49. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosages
50. Effects of estrogen on daylong circulating calcium, phosphorus, 1,25-dihydroxyvitamin D, and parathyroid hormone in postmenopausal women
51. Parathyroid growth, normal and abnormal
52. 2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism
53. Treatment of primary hyperparathyroidism
54. Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate
55. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis: A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase
56. Primary hyperparathyroidism in familial multiple endocrine neoplasia type I: Long-term follow-up of serum calcium levels after parathyroidectomy
57. Bone mass homeostasis and bisphosphonate action
58. Mechanisms of action of bisphosphonates
59. Late results of operation for primary hyperparathyroidism in 441 patients
60. Aminopropylidine diphosphonate (APD) in mild primary hyperparathyroidism: Effect on clinical status
61. Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women
62. Activated G protein-coupled receptor induces tyrosine phosphorylation of STAT3 and agonist-selective serine phosphorylation via sustained stimulation of mitogen-activated protein kinase: Resultant effects on cell proliferation
63. Parathyroid carcinoma
64. Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism
65. Therapy of hypercalcemia due to parathyroid carcinoma with intravenous dichloromethylene diphosphonate
66. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism
67. Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism
68. Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism
69. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery
70. Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism
71. Effect of alendronate (bisphosphonate) in animal models of hyperparathyroidism
72. Intravenous pamidronic acid in hypercalcemia due to parathyroid carcinoma
73. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency: Control of parathyroid cell growth via a calcium receptor
74. Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism
75. Treatment of postmenopausal hyperparathyroidism with norethindrone: Long-term effects on forearm mineral content
76. Parathyroid carcinoma: Clinical and pathologic features in 43 patients
77. Does estrogen replacement therapy influence parathyroid hormone responsiveness to exogenous hypercalcemia in postmenopausal women?